Clinical Trial

Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients

Study acronym: STREAMLINE
Recruiting
View on ClinicalTrials.gov →
Summary
Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI/non-STEMI in real-world settings in Russia. It is also planned to study the therapy effect on the lipid profile characteristics, its safety, the state of atherosclerotic plaques according to carotid ultrasound, the frequency of hospitalizations and the need for intensive follow-up.
Protocol Amendment History 4 changes
notable Trial sites expanded: 13 -> 16 locations 2026-05-12
notable Trial sites expanded: 7 -> 13 locations 2026-04-17
notable Primary completion pushed: 2027-03-31 -> 2027-09-30 2026-04-17
minor Completion pushed: 2027-03-31 -> 2027-09-30 2026-04-17
Trial Details
NCT Number NCT07142265
Lead Sponsor Novartis Pharmaceuticals
Conditions Myocardial Infarction
Enrollment 300 participants
Start Date 2025-09-30
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-10